PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target

Cancer Biology and Therapy

Volumn 16, Issue 2, 2015, Pages 219-224

  Gurung, Buddha ^a   Hua, Xianxin ^a   Runske, Melissa ^b   Bennett, Bonita ^b   LiVolsi, Virginia ^b   Roses, Robert ^b   Fraker, Douglas A ^a,b   Metz, David C ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hedgehog; MEN 1; Neuroendocrine; Pancreas

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMOGRANIN A; PROTEIN PATCHED 1; SMOOTHENED PROTEIN; SOMATOSTATIN DERIVATIVE; SONIC HEDGEHOG PROTEIN; VISMODEGIB; CELL SURFACE RECEPTOR; PATCHED RECEPTORS;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE MODEL; MULTIPLE ENDOCRINE NEOPLASIA; PANCREATIC NEUROENDOCRINE TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING; TREATMENT DURATION; UPREGULATION; CANCER GRADING; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; NEOPLASM GRADING; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84924620327     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.987574     Document Type: Article

References (28)

1. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-1492; PMID:18703061; http://dx.doi.org/10.1053/j.gastro.2008.05.047
2. Jensen RT, Berna MJ, Bingham MD, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008;113(7 Suppl):1807-43; http://dx.doi.org/10.1002/cncr.23648
3. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 18:276(5311):404-7; http://dx.doi.org/10.1126/science.276.5311.404
4. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005; 5:367-75; PMID:15864278; http://dx.doi.org/10.1038/nrc1610
5. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96, 143-152; PMID:9989505; http://dx.doi.org/10.1016/S0092-8674(00)80967-8
6. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 2004;13, 587-597; PMID:14992727; http://dx.doi.org/10.1016/S1097-2765(04)00081-4
7. Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol 2007; 265-266, 34-41; PMID:17222504; http://dx.doi.org/10.1016/j.mce.2006.12.032
8. Hunag J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X, Lei M. The same pocket in menin binds both MLL and JUN D but has opposite effects on transcription. Nature 2012;482:542-6; PMID:22327296; http://dx.doi.org/10.1038/nature10806
9. Knudson A. Mutation and cancer: statistical study of retinoblastoma. PNAS 1971; 68: 820-3; PMID: 5279523; http://dx.doi.org/10.1073/pnas.68.4.820
10. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011 Mar 4; 331(6021):1199-203; http://dx.doi.org/10.1126/science.1200609
11. Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin G, Fan CM, Ng JM, Curran T, Hua X. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res 2013; 73(8):2650-8; PMID:23580576; http://dx.doi.org/10.1158/0008-5472.CAN-12-3158
12. Meiss F, Zeiser R. Vismodegib. Recent Results Cancer Res 2014; 201:405-17; http://dx.doi.org/10.1007/978-3-642-54490-3-25
13. Gould SE, Low JA, Marsters JC Jr, Robarge K, Rubin LL, de Sauvage FJ, Sutherlin DP, Wong H, Yauch RL. Discovery and preclinical development of vismodegib. Expert Opin Drug Discov. 2014 Aug;9(8):969-84.
14. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134;1057-1063; PMID:14668741; http://dx.doi.org/10.1016/j.surg.2003.07.025
15. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663; PMID:19704057; http://dx.doi.org/10.1200/JCO.2009.22.8510
16. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sédláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, et al. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. NEJM 2014; 371: 224-233; PMID:25014687; http://dx.doi.org/10.1056/NEJMoa1316158
17. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Prac Res Clin Gastroenterol 2005; 19: 585-594; PMID:16183529; http://dx.doi.org/10.1016/j.bpg.2005.02.011
18. Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc and Intervent Radiol 2007; 18: 847-855; http://dx.doi.org/10.1016/j.jvir.2007.04.018
19. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275; PMID:20824724; http://dx.doi.org/10.1002/cncr.25425
20. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130; PMID:18445841; http://dx.doi.org/10.1200/JCO.2007.15.2553
21. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. NEJM 2011; 364: 501-513; PMID:21306237; http://dx.doi.org/10.1056/NEJMoa1003825
22. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res 2013; 73:1449-1453; PMID:23436795; http://dx.doi.org/10.1158/0008-5472.CAN-12-3923
23. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. NEJM 2012; 366:2171-2179; PMID:22670903; http://dx.doi.org/10.1056/NEJMoa1113713
24. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. NEJM 2012; 366:2180-2188; PMID:22670904; http://dx.doi.org/10.1056/NEJMoa1113538
25. Atwood SX, Whitson RJ, Oro AE. Advanced treatment for basal cell carcinomas. Cold Spring Harb Perspect Med 2014; 4:a013581; PMID:24985127; http://dx.doi.org/10.1101/cshperspect.a013581
26. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17:2502-2511; PMID:21300762; http://dx.doi.org/10.1158/1078-0432.CCR-10-2745
27. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23:824-833; PMID:20305616; http://dx.doi.org/10.1038/modpathol.2010.58
28. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO classification of tumours of the digestive system. (2010) IARC Press, Lyon, pp. 10-12.